Cited by

• Applying insights from biofilm biology to drug development - can a new approach be developed?

  Bjarnsholt T, Ciofu O, Molin S, Givskov M, Høiby N. Bjarnsholt T, et al. Nat Rev Drug Discov. 2013 Oct;12(10):791-808. doi: 10.1038/nrd4000. Nat Rev Drug Discov. 2013. PMID: 24080700 Review.
• Precipitating Pseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients.

  Trancassini M, de Vito D, Cimino G, Antonelli M, Quattrucci S, Cipriani P. Trancassini M, et al. Eur J Clin Microbiol Infect Dis. 1996 Apr;15(4):309-12. doi: 10.1007/BF01695663. Eur J Clin Microbiol Infect Dis. 1996. PMID: 8781882
• Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

  Govan JR, Deretic V. Govan JR, et al. Microbiol Rev. 1996 Sep;60(3):539-74. doi: 10.1128/mr.60.3.539-574.1996. Microbiol Rev. 1996. PMID: 8840786 Free PMC article. Review.
• From in vitro to in vivo Models of Bacterial Biofilm-Related Infections.

  Lebeaux D, Chauhan A, Rendueles O, Beloin C. Lebeaux D, et al. Pathogens. 2013 May 13;2(2):288-356. doi: 10.3390/pathogens2020288. Pathogens. 2013. PMID: 25437038 Free PMC article. Review.
• Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis.

  Boutin S, Graeber SY, Weitnauer M, Panitz J, Stahl M, Clausznitzer D, Kaderali L, Einarsson G, Tunney MM, Elborn JS, Mall MA, Dalpke AH. Boutin S, et al. PLoS One. 2015 Jan 28;10(1):e0116029. doi: 10.1371/journal.pone.0116029. eCollection 2015. PLoS One. 2015. PMID: 25629612 Free PMC article.